Compound 21 – Patient Worthy

source: shutterstock.com

Updated Interim Analysis of AIR Trial Shows C21 Promise for IPF

Post author:Jessica Lynn
Post published:June 8, 2023
Post category:Idiopathic Pulmonary Fibrosis

Currently, there are two FDA-approved treatments for people living with idiopathic pulmonary fibrosis (IPF): Ofev (nintedanib) and Esbriet (pirfenidone). While these therapies are effective in improving lung function, they…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More